Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 4/20 | 0.45 |
| ▸ | ATR | Q13535 | 3/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MELK | Q14680 | 9/20 | 0.39 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29217613 | 1.00 | ATM (0.45) | ATMATRPIK3CAMTORTLR9 | |
| SCHEMBL30012314 | 0.90 | ATM (0.48) | ATMATRPIK3CAMTORTLR9 | |
| SCHEMBL29217588 | 0.90 | ATM (0.48) | ATMATRPIK3CAMTORTLR9 | |
| SCHEMBL30012567 | 0.89 | MTOR (0.45) | ATMATRPIK3CAMTORTLR9 | |
| SCHEMBL29217578 | 0.89 | MTOR (0.45) | ATMATRPIK3CAMTORTLR9 | |
| SCHEMBL30839640 | 0.84 | ATM (0.41) | ATMATRPIK3CAMTORJAK1 | |
| SCHEMBL30012532 | 0.84 | ATM (0.41) | ATMATRPIK3CAMTORJAK1 | |
| SCHEMBL30011461 | 0.76 | ATM (0.42) | ATMATRPIK3CAMTORMELK | |
| SCHEMBL30011050 | 0.74 | MTOR (0.41) | ATMATRPIK3CAMTORMELK | |
| SCHEMBL29217570 | 0.71 | ATM (0.52) | ATMATRPIK3CAMTORTLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114026097-B | Substituted pyrazoloquinazolinone compounds and uses thereof | 上海瑛派药业有限公司 | 2024-02-23 | — | — | CN | claimed |
| US-20220259211-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-08-18 | — | — | US | claimed |
| CN-114026097-B | Substituted pyrazoloquinazolinone compounds and uses thereof | 上海瑛派药业有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20220259211-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259211-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF | CHEK1, CHEK2, ATM | ATM 3/4885ATR 4/4885PIK3CA 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.